You searched for "endotypes"

206 results found

Chronic rhinitis endotypes

Chronic rhinitis (CR) is common with up to 30% of the population affected, with a significant impact on quality of life. CR includes several phenotypes with different pathogenesis including allergy, autoimmune, age, occupation, pregnancy, neurogenic and drugs. Such variation means...

Endotypes in chronic rhinosinusitis: clinical relevance

Identifying endotypes enables personalised therapies that target specific pathophysiological processes, potentially resulting in better treatment outcomes for patients. The contemporary model of chronic rhinosinusitis (CRS) pathogenesis revolving around endotype, in combination with an expanding toolbox of diagnostics and therapeutics, enables...

Chronic rhinosinusitis, are we treating the same disease?

Chronic rhinosinusitis (CRS) is a heterogenic disease. The effects of heterogeneity on treatment outcome are not very clear. Authors used clinical features such as endoscopic findings scores and full blood count findings in addition to analysis of 35 molecular markers....

COVID-19 in patients with chronic rhinosinusitis with polyps. Are they at risk?

COVID-19 entry factors are highly present in nasal epithelial cells. These factors include ACE2 and TMPRSS2. Their presence in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) was not investigated before. Authors investigated expression of ACE2 and TMPRSS2 in two...

Biologic therapies for chronic rhinosinusitis with nasal polyps: a new paradigm

Surgery for nasal polyposis has evolved significantly in the last 30 years, and now the medical management may be on the cusp of a revolution. Biologics using monoclonal antibodies to target specific immune pathways have introduced a paradigm shift in...

Biologicals for severe chronic rhinosinusitis with nasal polyps. Any use?

Recent advances and knowledge of inflammatory endotypes of chronic rhinosinusitis with nasal polyps (CRSwNP) led to introduction of biological agents such as monoclonal antibodies targeting IgE (omalizumab) and Interleukins (ILs) such as IL4R alpha (dupilumab) and IL5. The European Academy...

From the editor May/Jun 2024

Declan Costello, MA, MBBS, FRCS(ORL-HNS),Consultant Ear, Nose and Throat Surgeon, Wexham Park Hospital, Slough, Berkshire, UK. E: d.costello@nhs.netTW / X: @Voicedoctor_uk One of the privileges of editing this magazine is interviewing senior figures within our specialty; so, it was wonderful...

Recalcitrant chronic rhinosinusitis: What to do next?

Whilst the majority of patients with chronic rhinosinusitis (CRS) will significantly improve with treatment, we are sometimes left with a ‘hard-core’ of nasal cripples who fail to improve despite our best efforts. How can we deal with these patients? Valerie...

Olfaction in CRS

Conventional teaching tells us that hyposmia in chronic rhinosinusitis is due to mechanical obstruction of the olfactory cleft. But it might be that the story is slightly more complicated than that. Olfactory dysfunction is a common feature of chronic rhinosinusitis...

Three-dimensional endoscopy for sinonasal procedures: is it really better?

In this interesting study the authors looked at the efficacy of two-dimensional (2D) versus 3D high-definition endoscopes in novice users, not those already trained in 2D. Ninety-two medical students used 2D and 3D endoscopes to complete two validated tasks and...

Rhinology: what does the future hold?

David Kennedy surveys the past, the present and the future of rhinology practice and research. An evolution of understanding in rhinology The dramatic growth of clinical and translational research within the field of rhinology in recent years is illustrated by...

The future of rhinology: What will come first, a radical change in rhinological management or the decimation of the world?

In this article, Simon Gane looks forward to what the future holds, on the presumption he survives. Setting aside the questions of the UK even existing, the NHS still working, or the fact we’ll be commuting to our jobs in...